The burden and clinical trajectory of immune checkpoint inhibitor-induced endocrinopathies: an 8-year experience.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) have revolutionized the management of cancer patients, but the emergence of ICI-related endocrinopathies (IREs) has introduced new clinical challenges. Despite worldwide recognition of these adverse effects, data from the Middle East is scarce.

Methods

This retrospective-observational study included adult cancer patients who received at least one dose of ICI between January 2015 and January 2023. Descriptive statistics and multivariable regression (MVR) models were applied to delineate the incidence and clinical impact of IREs.

Results

The median age of 649 included patients was 55 years, with male preponderance (70.7%). The incidence of IREs was 26.7%, dominated by primary hypothyroidism (62.4%), insulin deficiency (15%)

SUBMITTER: Ata F 

PROVIDER: S-EPMC11656579 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature